Advances in Bidirectional Therapy for Peritoneal Metastases: A Systematic Review of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined with Systemic Chemotherapy
Fortschritte in der bidirektionalen Therapie bei Peritonealmetastasen: systematische Übersichtsarbeit zu PIPAC in Kombination mit systemischer Chemotherapie
Cancers · 06.08.2025 · 17 (15) · 2580
DOI: 10.3390/cancers17152580 ↗Auf einen Blick
Die systematische Übersichtsarbeit zu PIPAC plus systemischer Chemotherapie bei Peritonealmetastasen fand in 22 Studien Hinweise auf machbare und potenziell wirksame Behandlungsergebnisse.
Fragestellung
Welche klinischen Ergebnisse, Sicherheit und methodische Qualität zeigen Studien zur bidirektionalen Therapie mit PIPAC und systemischer Chemotherapie bei Peritonealmetastasen?
Methode
Systematische Literaturrecherche in PubMed, Embase und Cochrane Library bis April 2025; eingeschlossen wurden Studien zu klinischen Ergebnissen unter bidirektionaler Therapie.
Ergebnisse
22 Studien mit 1015 Patient:innen, davon 742 mit bidirektionaler Therapie. Das mediane Gesamtüberleben lag bei 2,8 bis 19,6 Monaten; PRGS-Verbesserung wurde nach mehreren PIPAC-Zyklen in >80 % der beurteilbaren Fälle berichtet.
Einschränkungen
Retrospektive Natur und erhebliche Heterogenität der Behandlungsprotokolle, Responsekriterien, Systemregime und Toxizitätszuordnung.
Schlussfolgerung der Autor:innen
Die bidirektionale Therapie mit PIPAC und systemischer Chemotherapie erscheint als machbare und potenziell wirksame Strategie bei ausgewählten Patient:innen mit Peritonealmetastasen; definitive Schlüsse sind laut Autor:innen limitiert.
Kernaussagen
- 22 Studien mit 1015 Patient:innen wurden eingeschlossen
- Medianes Gesamtüberleben: 2,8 bis 19,6 Monate
- Heterogene Protokolle und überwiegend moderate methodische Qualität
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.08.2025. Verfasst von Manuela Robella und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Surgical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Peritoneal metastases (PM) represent a common and challenging manifestation of several gastrointestinal and gynecologic malignancies. Bidirectional treatment—combining Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with systemic chemotherapy—has emerged as a strategy to enhance locoregional control while maintaining systemic coverage.
Objective
This systematic review aimed to analyze the study design, characteristics, and timing of the treatments administered—including the type of systemic chemotherapy, intraperitoneal agents used in PIPAC, and interval between administrations—as well as the clinical outcomes, safety profile, and overall methodological quality of the available literature on bidirectional treatment for peritoneal metastases.
Methods
A systematic literature search was conducted across the PubMed, Embase, and Cochrane Library databases up to April 2025. Studies were included if they reported clinical outcomes of patients undergoing bidirectional treatment. Data extraction focused on survival, response assessment (PRGS, PCI), adverse events, systemic and intraperitoneal regimens, treatment interval, and study methodology.
Results
A total of 22 studies involving 1015 patients (742 treated with bidirectional therapy) were included. Median overall survival ranged from 2.8 to 19.6 months, with the most favorable outcomes observed in gastric and colorectal cancer cohorts. PRGS improvement after multiple PIPAC cycles was reported in >80% of evaluable cases. High-grade adverse events (CTCAE ≥ 3) occurred in up to 17% of patients in most studies, with only one study reporting treatment-related mortality. However, methodological quality was generally moderate, with considerable heterogeneity in treatment protocols, response criteria, systemic regimens, and toxicity attribution.
Conclusions
Bidirectional therapy with PIPAC and systemic chemotherapy appears to be a feasible and potentially effective strategy for selected patients with peritoneal metastases. Despite encouraging outcomes, definitive conclusions are limited by the retrospective nature and heterogeneity of available studies. Prospective standardized trials are needed to confirm efficacy, clarify patient selection, and optimize treatment protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Surgical Oncology, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy.
- Centre for Biostatistics, Epidemiology and Public Health, Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
- Surgical Unit of Peritoneum and Retroperitoneum Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- General Surgery Department, Universita' Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Department of Visceral Surgery, Lausanne University Hospital, University of Lausanne, 1005 Lausanne, Switzerland.
- Department of Surgical Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
ORCID-Profile: Manuela Robella, Marco Vitturini, Andrea Di Giorgio, Martin Hubner, Emanuele Koumantakis, Paolo Catania, Paola Berchialla
Zitieren
APA
Robella, M., Vitturini, M., Di Giorgio, A., Aulicino, M., Hubner, M., Koumantakis, E., Borghi, F., Catania, P., Cinquegrana, A., & Berchialla, P. (2025). Advances in Bidirectional Therapy for Peritoneal Metastases: A Systematic Review of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined with Systemic Chemotherapy. Cancers, 17(15), 2580. https://doi.org/10.3390/cancers17152580
Vancouver
Robella M, Vitturini M, Di Giorgio A, Aulicino M, Hubner M, Koumantakis E, et al. Advances in Bidirectional Therapy for Peritoneal Metastases: A Systematic Review of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined with Systemic Chemotherapy. Cancers. 2025;17(15):2580. doi:10.3390/cancers17152580
BibTeX
@article{Robella2025,
author = {Robella, Manuela and Vitturini, Marco and Di Giorgio, Andrea and Aulicino, Matteo and Hubner, Martin and Koumantakis, Emanuele and Borghi, Felice and Catania, Paolo and Cinquegrana, Armando and Berchialla, Paola},
title = {Advances in Bidirectional Therapy for Peritoneal Metastases: A Systematic Review of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined with Systemic Chemotherapy},
journal = {Cancers},
year = {2025},
volume = {17},
number = {15},
pages = {2580},
doi = {10.3390/cancers17152580}
}
EUVIMED